PB

Pfizer Breakthrough Growth Initiative

Description

Pfizer Breakthrough Growth Initiative provide funding to biotechnology companies.

Investor Profile

Pfizer Breakthrough Growth Initiative has backed more than 3 startups, with 0 new investments in the last 12 months alone. The firm has led 2 rounds, about 67% of its total and boasts 6 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series A, Post Ipo Equity, Series B rounds (top funding stages).
  • Majority of deals are located in United States, Canada, Belgium.
  • Strong thematic focus on Biotechnology, Therapeutics, Health Care.

Stage Focus

  • Series A (33%)
  • Post Ipo Equity (33%)
  • Series B (33%)

Country Focus

  • United States (33%)
  • Canada (33%)
  • Belgium (33%)

Industry Focus

  • Biotechnology
  • Therapeutics
  • Health Care
  • Pharmaceutical
  • Biopharma
  • Clinical Trials
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Pfizer Breakthrough Growth Initiative frequently co-invest with?

Angelini Ventures
Europe, Lazio, Italy, Rome
Co-Investments: 1
Asabys Partners
Europe, Catalonia, Spain, Barcelona
Co-Investments: 1
Bristol-Myers Squibb
North America, New York, United States, New York
Co-Investments: 1
JDRF T1D Fund
North America, Massachusetts, United States, Boston
Co-Investments: 1
Lumira Ventures
North America, Ontario, Canada, Toronto
Co-Investments: 1
Frazier Healthcare Partners
North America, Washington, United States, Seattle
Co-Investments: 1
AW
North America, Florida, United States, Miami
Co-Investments: 1
Roche Venture Fund
Europe, Basel-Stadt, Switzerland, Basel
Co-Investments: 1
Walleye Capital
North America, Minnesota, United States, Plymouth
Co-Investments: 1

What are some of recent deals done by Pfizer Breakthrough Growth Initiative?

Cour Pharmaceuticals Development

Skokie, Illinois, United States

Cour Pharmaceuticals Development is developing nanoparticle technology to help reset the immune system of multiple sclerosis (MS) patients.

BiotechnologyPharmaceuticalTherapeutics
Series AJan 30, 2024
Amount Raised: $105,000,000
AgomAb Therapeutics

Ghent, Oost-Vlaanderen, Belgium

AgomAb Therapeutics is a Company is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues.

BiotechnologyHealth CareTherapeutics
Series BJul 13, 2022
Amount Raised: $38,531,817
Trillium Therapeutics

Toronto, Ontario, Canada

Trillium is a biotech company focused on developing therapy treatments for cancer.

BiopharmaBiotechnologyClinical TrialsHealth CareTherapeutics
Post Ipo EquitySep 8, 2020
Amount Raised: $25,000,000